百时美施贵宝公司将以74亿美元的医药交易收购Celgene_老虎社区_美港股上老虎

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":369644,"tweetId":"369644","gmtCreate":1546518557502,"gmtModify":1704785651890,"author":{"id":34550872632897,"idStr":"34550872632897","authorId":34550872632897,"authorIdStr":"34550872632897","name":"今日新闻","avatar":"https://static.tigerbbs.com/17e95cbcbf19f0309585055e187b66cb","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1554,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"百时美施贵宝公司将以74亿美元的医药交易收购Celgene","extraTitle":"","html":"<html><head></head><body>（彭博社）$施贵宝(BMY)$同意收购$新基公司(CELG)$公司 以740亿美元的现金和股票交易，创建一家可与世界上最大的制药商竞争的制药巨头。 施贵宝盘前下跌10%，新基盘前上涨30% 根据周四的一份声明，Celgene的股东将获得一份百时美施贵宝股票和每股Celgene股票的50美元现金。 重要见解 该协议将把重磅炸弹抗癌药物Revlimid添加到Bristol-Myers Squibb的阵容中。两家公司表示，合并后的公司将拥有9款年销售额超过10亿美元的产品。他们认为“肿瘤学，免疫学，炎症和心血管疾病等核心疾病领域的增长潜力巨大。” 据报道，摩根士丹利和MUFG正在提供承诺的债务融资 摩根士丹利还是施贵宝的首席财务顾问 交易的现金部分也由手头现金提供资金 </body></html>","htmlText":"<html><head></head><body>（彭博社）$施贵宝(BMY)$同意收购$新基公司(CELG)$公司 以740亿美元的现金和股票交易，创建一家可与世界上最大的制药商竞争的制药巨头。 施贵宝盘前下跌10%，新基盘前上涨30% 根据周四的一份声明，Celgene的股东将获得一份百时美施贵宝股票和每股Celgene股票的50美元现金。 重要见解 该协议将把重磅炸弹抗癌药物Revlimid添加到Bristol-Myers Squibb的阵容中。两家公司表示，合并后的公司将拥有9款年销售额超过10亿美元的产品。他们认为“肿瘤学，免疫学，炎症和心血管疾病等核心疾病领域的增长潜力巨大。” 据报道，摩根士丹利和MUFG正在提供承诺的债务融资 摩根士丹利还是施贵宝的首席财务顾问 交易的现金部分也由手头现金提供资金 </body></html>","text":"（彭博社）$施贵宝(BMY)$同意收购$新基公司(CELG)$公司 以740亿美元的现金和股票交易，创建一家可与世界上最大的制药商竞争的制药巨头。 施贵宝盘前下跌10%，新基盘前上涨30% 根据周四的一份声明，Celgene的股东将获得一份百时美施贵宝股票和每股Celgene股票的50美元现金。 重要见解 该协议将把重磅炸弹抗癌药物Revlimid添加到Bristol-Myers Squibb的阵容中。两家公司表示，合并后的公司将拥有9款年销售额超过10亿美元的产品。他们认为“肿瘤学，免疫学，炎症和心血管疾病等核心疾病领域的增长潜力巨大。” 据报道，摩根士丹利和MUFG正在提供承诺的债务融资 摩根士丹利还是施贵宝的首席财务顾问 交易的现金部分也由手头现金提供资金","highlighted":1,"essential":2,"paper":2,"likeSize":6,"commentSize":2,"repostSize":1,"favoriteSize":0,"link":"https://laohu8.com/post/369644","repostId":0,"isVote":1,"tweetType":1,"viewCount":11362,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["BMY","CELG"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":562,"xxTargetLangEnum":"ZH_CN"},"commentList":[{"id":1252349,"commentId":"1252349","gmtCreate":1546520537692,"gmtModify":1546520537692,"authorId":3481770198526736,"author":{"id":3481770198526736,"idStr":"3481770198526736","authorId":3481770198526736,"name":"dwyl","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":369644,"objectIdStr":"369644","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"终于等到收购解套了","text":"终于等到收购解套了","html":"终于等到收购解套了","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0},{"id":1252327,"commentId":"1252327","gmtCreate":1546520045202,"gmtModify":1546520045202,"authorId":3479156248791467,"author":{"id":3479156248791467,"idStr":"3479156248791467","authorId":3479156248791467,"name":"复兴计划","avatar":"https://static.tigerbbs.com/c10d2ba3aa6d31cda64398d07bf813cb","vip":1,"hat":"https://static.tigerbbs.com/d30fc324d24ff33075e053005564f0df","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":369644,"objectIdStr":"369644","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"哪位分析下套利","text":"哪位分析下套利","html":"哪位分析下套利","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0}],"hasMoreComment":true,"orderType":2}

百时美施贵宝公司将以74亿美元的医药交易收购Celgene

评论（2）

热议股票